Lymphopenia during 177Lu-DOTATATE therapy leading to recurrence of tuberculosis: a case report
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2510-3636
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Lymphopenia during 177Lu-DOTATATE therapy leading to recurrence of tuberculosis: a case report ; volume:6 ; number:1 ; day:13 ; month:12 ; year:2022 ; pages:1-7 ; date:12.2022
European journal of hybrid imaging ; 6, Heft 1 (13.12.2022), 1-7, 12.2022
- Creator
-
Boughdad, Sarah
Mota, Michael Da
Mendes De Carvalho, Mélanie
Firsova, Maria
Prior, John O.
Schaefer, Niklaus
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s41824-022-00157-y
- URN
-
urn:nbn:de:101:1-2023021909110440876912
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:58 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Boughdad, Sarah
- Mota, Michael Da
- Mendes De Carvalho, Mélanie
- Firsova, Maria
- Prior, John O.
- Schaefer, Niklaus
- SpringerLink (Online service)
Other Objects (12)
90Y/177Lu-DOTATATE therapy: survival of the fittest?
Tissue dose estimation after extravasation of 177Lu-DOTATATE
Concomitant 177Lu-DOTATATE and capecitabine therapy in malignant paragangliomas
p53 stabilisation potentiates [177Lu]Lu-DOTATATE treatment in neuroblastoma xenografts
Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry
Dosimetric implications of kidney anatomical volume changes in 177Lu-DOTATATE therapy
Einfluss der Peptid-Radio-Rezeptor-Therapie mittels 90Y- und 177Lu-DOTATATE auf die inflammatorische Atheroskleroseaktivität : Therapiemonitoring mittels serieller 68Ga-DOTATATE Positronenemissionstomographie, Computertomographie
Accuracy and precision assessment for activity quantification in individualized dosimetry of 177Lu-DOTATATE therapy
Practical kidney dosimetry in peptide receptor radionuclide therapy using [177Lu]Lu-DOTATOC and [177Lu]Lu-DOTATATE with focus on uncertainty estimates
Predicting [177Lu]Lu-HA-DOTATATE kidney and tumor accumulation based on [68Ga]Ga-HA-DOTATATE diagnostic imaging using semi-physiological population pharmacokinetic modeling
Dose mapping after endoradiotherapy with 177Lu-DOTATATE/DOTATOC by a single measurement after 4 days
Radiation precautions for inpatient and outpatient 177Lu-DOTATATE peptide receptor radionuclide therapy of neuroendocrine tumours
90Y/177Lu-DOTATATE therapy: survival of the fittest?
Tissue dose estimation after extravasation of 177Lu-DOTATATE
Concomitant 177Lu-DOTATATE and capecitabine therapy in malignant paragangliomas
p53 stabilisation potentiates [177Lu]Lu-DOTATATE treatment in neuroblastoma xenografts
Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry
Dosimetric implications of kidney anatomical volume changes in 177Lu-DOTATATE therapy
Einfluss der Peptid-Radio-Rezeptor-Therapie mittels 90Y- und 177Lu-DOTATATE auf die inflammatorische Atheroskleroseaktivität : Therapiemonitoring mittels serieller 68Ga-DOTATATE Positronenemissionstomographie, Computertomographie
Accuracy and precision assessment for activity quantification in individualized dosimetry of 177Lu-DOTATATE therapy
Practical kidney dosimetry in peptide receptor radionuclide therapy using [177Lu]Lu-DOTATOC and [177Lu]Lu-DOTATATE with focus on uncertainty estimates
Predicting [177Lu]Lu-HA-DOTATATE kidney and tumor accumulation based on [68Ga]Ga-HA-DOTATATE diagnostic imaging using semi-physiological population pharmacokinetic modeling
Dose mapping after endoradiotherapy with 177Lu-DOTATATE/DOTATOC by a single measurement after 4 days
Radiation precautions for inpatient and outpatient 177Lu-DOTATATE peptide receptor radionuclide therapy of neuroendocrine tumours
90Y/177Lu-DOTATATE therapy: survival of the fittest?
Tissue dose estimation after extravasation of 177Lu-DOTATATE
Concomitant 177Lu-DOTATATE and capecitabine therapy in malignant paragangliomas
p53 stabilisation potentiates [177Lu]Lu-DOTATATE treatment in neuroblastoma xenografts
Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry
Dosimetric implications of kidney anatomical volume changes in 177Lu-DOTATATE therapy
Einfluss der Peptid-Radio-Rezeptor-Therapie mittels 90Y- und 177Lu-DOTATATE auf die inflammatorische Atheroskleroseaktivität : Therapiemonitoring mittels serieller 68Ga-DOTATATE Positronenemissionstomographie, Computertomographie
Accuracy and precision assessment for activity quantification in individualized dosimetry of 177Lu-DOTATATE therapy
Practical kidney dosimetry in peptide receptor radionuclide therapy using [177Lu]Lu-DOTATOC and [177Lu]Lu-DOTATATE with focus on uncertainty estimates
Predicting [177Lu]Lu-HA-DOTATATE kidney and tumor accumulation based on [68Ga]Ga-HA-DOTATATE diagnostic imaging using semi-physiological population pharmacokinetic modeling
Dose mapping after endoradiotherapy with 177Lu-DOTATATE/DOTATOC by a single measurement after 4 days